Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?

Rudolf Valenta, Alexander Karaulov, Verena Niederberger, Yury Zhernov, Olga Elisyutina, Raffaela Campana, Margarete Focke-Tejkl, Mirela Curin, Leyla Namazova-Baranova, Jiu-Yao Wang, Ruby Pawankar, Musa Khaitov

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural allergen sources. Several studies analyzing the composition of natural allergen extracts have shown severe problems regarding their quality such as the presence of undefined nonallergenic materials, contaminants as well as high variabilities regarding contents and biological activity of individual allergens. Despite the increasing availability of sophisticated analytical technologies, these problems cannot be overcome because they are inherent to allergen sources and methods of extract production. For in vitro allergy diagnosis problems related to natural allergen extracts have been largely overcome by the implementation of recombinant allergen molecules that are defined regarding purity and biological activity. However, no such advances have been made for allergen preparations to be used in vivo for diagnosis and therapy. No clinical studies have been performed for allergen extracts available for in vivo allergy diagnosis that document safety, sensitivity, and specificity of the products. Only for very few therapeutic allergen extracts state-of-the-art clinical studies have been performed that provide evidence for safety and efficacy. In this article, we discuss problems related to the inconsistent quality of products based on natural allergen extracts and share our observations that most of the products available for in vivo diagnosis and AIT do not meet the international standards for medicinal products. We argue that a replacement of natural allergen extracts by defined recombinantly produced allergen molecules and/or mixtures thereof may be the only way to guarantee the supply of clinicians with state-of-the-art medicinal products for in vivo diagnosis and treatment of allergic patients in the future.

Original languageEnglish
Pages (from-to)1845-1855.e2
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume6
Issue number6
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

Allergens
Hypersensitivity
Therapeutics
Immunologic Desensitization
Safety
Technology
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Valenta, R., Karaulov, A., Niederberger, V., Zhernov, Y., Elisyutina, O., Campana, R., ... Khaitov, M. (2018). Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? Journal of Allergy and Clinical Immunology: In Practice, 6(6), 1845-1855.e2. https://doi.org/10.1016/j.jaip.2018.08.032
Valenta, Rudolf ; Karaulov, Alexander ; Niederberger, Verena ; Zhernov, Yury ; Elisyutina, Olga ; Campana, Raffaela ; Focke-Tejkl, Margarete ; Curin, Mirela ; Namazova-Baranova, Leyla ; Wang, Jiu-Yao ; Pawankar, Ruby ; Khaitov, Musa. / Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy : Is There a Future?. In: Journal of Allergy and Clinical Immunology: In Practice. 2018 ; Vol. 6, No. 6. pp. 1845-1855.e2.
@article{b94fb6c03e8f4a1a9870df0ed4de4b1a,
title = "Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?",
abstract = "Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural allergen sources. Several studies analyzing the composition of natural allergen extracts have shown severe problems regarding their quality such as the presence of undefined nonallergenic materials, contaminants as well as high variabilities regarding contents and biological activity of individual allergens. Despite the increasing availability of sophisticated analytical technologies, these problems cannot be overcome because they are inherent to allergen sources and methods of extract production. For in vitro allergy diagnosis problems related to natural allergen extracts have been largely overcome by the implementation of recombinant allergen molecules that are defined regarding purity and biological activity. However, no such advances have been made for allergen preparations to be used in vivo for diagnosis and therapy. No clinical studies have been performed for allergen extracts available for in vivo allergy diagnosis that document safety, sensitivity, and specificity of the products. Only for very few therapeutic allergen extracts state-of-the-art clinical studies have been performed that provide evidence for safety and efficacy. In this article, we discuss problems related to the inconsistent quality of products based on natural allergen extracts and share our observations that most of the products available for in vivo diagnosis and AIT do not meet the international standards for medicinal products. We argue that a replacement of natural allergen extracts by defined recombinantly produced allergen molecules and/or mixtures thereof may be the only way to guarantee the supply of clinicians with state-of-the-art medicinal products for in vivo diagnosis and treatment of allergic patients in the future.",
author = "Rudolf Valenta and Alexander Karaulov and Verena Niederberger and Yury Zhernov and Olga Elisyutina and Raffaela Campana and Margarete Focke-Tejkl and Mirela Curin and Leyla Namazova-Baranova and Jiu-Yao Wang and Ruby Pawankar and Musa Khaitov",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.jaip.2018.08.032",
language = "English",
volume = "6",
pages = "1845--1855.e2",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "6",

}

Valenta, R, Karaulov, A, Niederberger, V, Zhernov, Y, Elisyutina, O, Campana, R, Focke-Tejkl, M, Curin, M, Namazova-Baranova, L, Wang, J-Y, Pawankar, R & Khaitov, M 2018, 'Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?', Journal of Allergy and Clinical Immunology: In Practice, vol. 6, no. 6, pp. 1845-1855.e2. https://doi.org/10.1016/j.jaip.2018.08.032

Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy : Is There a Future? / Valenta, Rudolf; Karaulov, Alexander; Niederberger, Verena; Zhernov, Yury; Elisyutina, Olga; Campana, Raffaela; Focke-Tejkl, Margarete; Curin, Mirela; Namazova-Baranova, Leyla; Wang, Jiu-Yao; Pawankar, Ruby; Khaitov, Musa.

In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, No. 6, 01.11.2018, p. 1845-1855.e2.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy

T2 - Is There a Future?

AU - Valenta, Rudolf

AU - Karaulov, Alexander

AU - Niederberger, Verena

AU - Zhernov, Yury

AU - Elisyutina, Olga

AU - Campana, Raffaela

AU - Focke-Tejkl, Margarete

AU - Curin, Mirela

AU - Namazova-Baranova, Leyla

AU - Wang, Jiu-Yao

AU - Pawankar, Ruby

AU - Khaitov, Musa

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural allergen sources. Several studies analyzing the composition of natural allergen extracts have shown severe problems regarding their quality such as the presence of undefined nonallergenic materials, contaminants as well as high variabilities regarding contents and biological activity of individual allergens. Despite the increasing availability of sophisticated analytical technologies, these problems cannot be overcome because they are inherent to allergen sources and methods of extract production. For in vitro allergy diagnosis problems related to natural allergen extracts have been largely overcome by the implementation of recombinant allergen molecules that are defined regarding purity and biological activity. However, no such advances have been made for allergen preparations to be used in vivo for diagnosis and therapy. No clinical studies have been performed for allergen extracts available for in vivo allergy diagnosis that document safety, sensitivity, and specificity of the products. Only for very few therapeutic allergen extracts state-of-the-art clinical studies have been performed that provide evidence for safety and efficacy. In this article, we discuss problems related to the inconsistent quality of products based on natural allergen extracts and share our observations that most of the products available for in vivo diagnosis and AIT do not meet the international standards for medicinal products. We argue that a replacement of natural allergen extracts by defined recombinantly produced allergen molecules and/or mixtures thereof may be the only way to guarantee the supply of clinicians with state-of-the-art medicinal products for in vivo diagnosis and treatment of allergic patients in the future.

AB - Today, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergen extracts obtained from natural allergen sources. Several studies analyzing the composition of natural allergen extracts have shown severe problems regarding their quality such as the presence of undefined nonallergenic materials, contaminants as well as high variabilities regarding contents and biological activity of individual allergens. Despite the increasing availability of sophisticated analytical technologies, these problems cannot be overcome because they are inherent to allergen sources and methods of extract production. For in vitro allergy diagnosis problems related to natural allergen extracts have been largely overcome by the implementation of recombinant allergen molecules that are defined regarding purity and biological activity. However, no such advances have been made for allergen preparations to be used in vivo for diagnosis and therapy. No clinical studies have been performed for allergen extracts available for in vivo allergy diagnosis that document safety, sensitivity, and specificity of the products. Only for very few therapeutic allergen extracts state-of-the-art clinical studies have been performed that provide evidence for safety and efficacy. In this article, we discuss problems related to the inconsistent quality of products based on natural allergen extracts and share our observations that most of the products available for in vivo diagnosis and AIT do not meet the international standards for medicinal products. We argue that a replacement of natural allergen extracts by defined recombinantly produced allergen molecules and/or mixtures thereof may be the only way to guarantee the supply of clinicians with state-of-the-art medicinal products for in vivo diagnosis and treatment of allergic patients in the future.

UR - http://www.scopus.com/inward/record.url?scp=85054487735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054487735&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2018.08.032

DO - 10.1016/j.jaip.2018.08.032

M3 - Review article

C2 - 30297269

AN - SCOPUS:85054487735

VL - 6

SP - 1845-1855.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

IS - 6

ER -